WAVE LIFE SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.62 USD | -2.43% |
|
-8.47% | +11.29% |
| 05-09 | Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-09 | Earnings Flash (WVE) WAVE LIFE SCIENCES USA Posts Q1 Revenue $12.5M, vs. Street Est of $23M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 78.53M 107M | Sales 2025 * | 52.83M 72.21M | Capitalization | 687M 940M |
|---|---|---|---|---|---|
| Net income 2024 * | -118M -161M | Net income 2025 * | -138M -189M | EV / Sales 2024 * | 6.64 x |
| Net cash position 2024 * | 166M 227M | Net cash position 2025 * | 113M 154M | EV / Sales 2025 * | 10.9 x |
| P/E ratio 2024 * |
-6.08
x | P/E ratio 2025 * |
-5.81
x | Employees | 267 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Wave Life Sciences Ltd.
More recommendations
More press releases
| 1 day | -2.43% | ||
| 1 week | -8.47% | ||
| Current month | +14.00% | ||
| 1 month | -6.95% | ||
| 3 months | +37.07% | ||
| 6 months | +7.05% | ||
| Current year | +11.29% |
1 week
5.28
6.20
1 month
4.646.38
Current year
3.507.67
1 year
3.157.67
3 years
1.167.67
5 years
1.1639.98
10 years
1.1656.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Bolno
CEO | Chief Executive Officer | 50 | 13-11-30 |
Kyle Moran
DFI | Director of Finance/CFO | 54 | 14-06-30 |
Chandra Vargeese
CTO | Chief Tech/Sci/R&D Officer | 63 | 14-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Henry
CHM | Chairman | 56 | 16-11-09 |
Mark Corrigan
BRD | Director/Board Member | 66 | 19-09-03 |
Adrian Rawcliffe
BRD | Director/Board Member | 52 | 17-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 5.62 | -2.43% | 525,905 |
| 24-05-09 | 5.76 | -1.54% | 531,735 |
| 24-05-08 | 5.85 | +1.04% | 737,434 |
| 24-05-07 | 5.79 | +0.70% | 867,578 |
| 24-05-06 | 5.75 | -6.35% | 908,530 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm
More quotes
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntingtonâs disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.62
USD
Average target price
13.17
USD
Spread / Average Target
+134.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.29% | 687M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- WVE Stock